We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Personal Continuous Glucose Monitoring Device Validated

By LabMedica International staff writers
Posted on 17 Sep 2008
A personal continuous glucose-monitoring (CGM) device significantly reduced the average blood glucose levels (A1c) of adult patients with type 1 diabetes. More...
This further validated the ability of the device to substantially improve diabetes management and glucose control. Reducing A1c can result in reduced risk of long-term side effects associated with diabetes, including blindness and kidney disease.

A multicenter, 322-patient trial, funded by the Juvenile Diabetes Research Foundation (JDRF; New York, NY, USA), found that after six months adults using the personal CGM realized a statistically significant 0.53% absolute reduction in A1c as compared to the control group. All patients in the study experienced statistically significant absolute reductions in A1c levels ranging from 0.5-0.7% when the personal CGM was used at least six days a week. Moreover, improvements in A1c occurred without an increase in severe hypoglycemia (low blood sugar).

Medtronic (Northridge, CA, USA) currently markets the integrated diabetes management system that combines the personal CGM with insulin pump therapy. It is called the MiniMed Paradigm Real-Time system. Medtronic also offers a stand-alone personal CGM device--the Guardian Real-Time system.

Medtronic is a world leader in advanced diabetes management solutions. Their products include integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems, and therapy management software.

"We are confident that the JDRF study results will aid physicians' efforts to bring personal CGM to more patients,” said Chris O'Connell, president of the diabetes business at Medtronic. "In fact, healthcare insurers are already seeing value in this technology. Many have policies for personal CGM devices, and new coverage decisions are being made regularly.”

Results from the multicenter study were presented on September 8, 2008, during the European Association for the Study of Diabetes annual meeting in Rome, Italy, and portions of the data will be published in the October 2, 2008, issue of the New England Journal of Medicine, which is also available online.

Related Links:
Juvenile Diabetes Research Foundation
Medtronics


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Blood Glucose Test Strip
AutoSense Test
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more

Technology

view channel
Image: The newly designed ExoPatch successfully distinguished melanoma from healthy skin in mice (Photo courtesy of Jeremy Little/Michigan Engineering)

Microneedle Skin Patch Detects Melanoma Without Biopsy or Blood Draw

Melanoma, the most aggressive form of skin cancer, currently requires patients, especially those with fair skin and moles, to undergo regular doctor visits and biopsies every six months to determine if... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.